Would you consider anti-IL-5 therapy (mepolizumab or benralizumab) to either prevent or treat the more severe manifestations of eosinophilic granulomatosis with polyangiitis, such as "infiltrative" (e.g., cardiomyopathy, pulmonary infiltrates, or gastroenteritis) or "vasculitic" (e.g., neuropathy, palpable purpura, or glomerulonephritis)?

Yes, I would consider early starting biologics for infiltrative EGPA.

Currently available data for mepolizumab and benralizumab suggest that they provide a benefit for preventing relapse across disease manifestations, suggesting there is efficacy across both infiltrative and vasculitic manifestations. However, there is no robust data on induction outcomes in patients ...